List view / Grid view
29 July 2014 | By Novartis
Novartis has announced the initial results of a large-scale vaccination campaign with Bexsero® to help protect against meningitis B within the Saguenay-Lac-Saint-Jean region of Québec, Canada...
28 July 2014 | By Novartis
Alcon, the global leader in eye care and a division of Novartis, announced that Simbrinza® eye drops suspension (brinzolamide 10mg/mL and brimonidine tartrate 2mg/mL) has been approved by the European Commission...
24 July 2014 | By Novartis
Sandoz announced that the US Food and Drug Administration has accepted its Biologics License Application for filgrastim...
15 July 2014 | By Novartis
Novartis announced a collaboration with Banner Alzheimer's Institute on a pioneering clinical study in Alzheimer's disease (AD) prevention...
9 July 2014 | By Novartis
Novartis has published a Corporate Responsibility (CR) Performance Report for 2013...
8 July 2014 | By Novartis
Novartis released new global guidelines for Investigator Initiated Trials...
30 June 2014 | By Novartis
Sandoz announces a long-term commitment to help prevent the deaths of millions of children worldwide by supplying a key antibiotic formulation...
18 June 2014 | By Novartis
For its first "Meet Novartis Management" investor day, Novartis gathered more than 20 of its top executives, drawn from the leadership of Pharmaceuticals...
17 June 2014 | By Novartis
Novartis announced the submission of a Biologic License Application to the US Food and Drug Administration for marketing approval for the use of Bexsero® (Multicomponent Meningococcal Group B Vaccine...
16 June 2014 | By Novartis
Novartis announced that the US Food and Drug Administration licensed its manufacturing facility in Holly Springs, N.C. for the production of cell-culture influenza vaccines...
10 June 2014 | By Novartis
The Novartis Foundation for Sustainable Development and Netherlands Leprosy Relief announced their collaboration with national leprosy programs and other International Federation of Anti-Leprosy Associations...
4 June 2014 | By Novartis
Novartis announced results from the first-ever pivotal Phase III study evaluating a JAK 1/2 inhibitor for the treatment of polycythemia vera (PV). Jakavi® (ruxolitinib) significantly improved hematocrit control without the need for phlebotomy...
2 June 2014 | By Novartis
Novartis announced the appointment of Bruno Strigini, as President of Novartis Oncology...
23 May 2014 | By Novartis
Novartis announced that the Committee for Medicinal Products for Human Use has adopted a negative opinion for the use of RLX030 in the treatment of acute heart failure...
22 May 2014 | By Novartis
Novartis will showcase the results of research efforts to target disease pathways with more than 150 abstracts at two upcoming cancer-focused meetings...
